Global Rivaroxaban Market to Reach US$22.4 Billion by 2030
The global market for Rivaroxaban estimated at US$16.3 Billion in the year 2024, is expected to reach US$22.4 Billion by 2030, growing at a CAGR of 5.5% over the analysis period 2024-2030. Atrial Fibrillation Indication, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$9.0 Billion by the end of the analysis period. Growth in the Deep Vein Thrombosis Indication segment is estimated at 4.0% CAGR over the analysis period.
The U.S. Market is Estimated at US$4.4 Billion While China is Forecast to Grow at 9.0% CAGR
The Rivaroxaban market in the U.S. is estimated at US$4.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.6 Billion by the year 2030 trailing a CAGR of 9.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.6% and 5.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.
Global “Rivaroxaban” Market - Key Trends & Drivers Summarized
Why Is Rivaroxaban Emerging as a Cornerstone in Anticoagulant Therapy?
Rivaroxaban, an oral anticoagulant belonging to the class of direct Factor Xa inhibitors, is revolutionizing the treatment and prevention of thromboembolic disorders. Developed as a more convenient alternative to traditional vitamin K antagonists like warfarin, Rivaroxaban provides predictable pharmacokinetics, fixed dosing, and minimal dietary or drug interactions, significantly improving patient adherence. It is widely used for indications such as stroke prevention in non-valvular atrial fibrillation (AF), treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and prophylaxis following orthopedic surgeries. The global aging population and rising incidence of cardiovascular diseases have drastically expanded the eligible patient pool. Furthermore, increased awareness of atrial fibrillation and its complications has led to earlier diagnoses and longer-term anticoagulation needs. Real-world evidence continues to reinforce Rivaroxaban’s clinical efficacy and safety, while ongoing head-to-head studies demonstrate favorable outcomes compared to other NOACs (non-vitamin K antagonist oral anticoagulants). The simplicity of use-no routine coagulation monitoring-and reduced risk of intracranial bleeding versus warfarin, make it a preferred choice among clinicians. Additionally, the convenience of once-daily dosing distinguishes it from certain competitors that require twice-daily regimens, supporting better compliance in long-term use cases.
How Are Patent Lifecycles and Generics Impacting the Market Structure?
As Rivaroxaban approaches patent expiry in major markets, the competitive landscape is undergoing a significant transformation. Branded versions, such as Xarelto® (developed by Bayer and marketed with Johnson & Johnson), have enjoyed exclusivity in high-value territories for years. However, the impending and ongoing entry of generic formulations is set to disrupt pricing dynamics and increase accessibility. Manufacturers in countries like India, China, and Brazil are preparing for expanded generic production to capitalize on newly opened markets. The introduction of bioequivalent generics is expected to lower treatment costs, particularly in cost-sensitive public health systems. Regulatory bodies such as the FDA and EMA have established fast-track processes for high-priority generics, accelerating their launch timelines. While this benefits patients and payers, it presents challenges for branded manufacturers in maintaining market share. In response, originator companies are investing in extended indications, fixed-dose combination therapies, and digital patient support platforms. Moreover, evolving reimbursement models in the US, EU, and APAC regions are creating tiered pricing strategies, forcing companies to align marketing and distribution efforts by geography and payer structure. The interplay between innovation lifecycle management and generic competition will shape the market’s pricing elasticity and volume growth.
Which Clinical Trends and Therapeutic Expansions Are Enhancing Market Potential?
Rivaroxaban’s role is expanding beyond its core indications into a broader set of cardiovascular and thromboembolic conditions. Recent approvals and trials have highlighted its use in secondary prevention of acute coronary syndrome (ACS) and peripheral artery disease (PAD), particularly in patients with coexisting conditions like diabetes or renal dysfunction. Emerging evidence supports Rivaroxaban’s utility in cancer-associated thrombosis, where conventional anticoagulants pose higher bleeding risks. Several Phase III trials are also exploring Rivaroxaban in conjunction with antiplatelet agents to prevent cardiovascular events in high-risk patients. The growing preference for oral over parenteral anticoagulation in hospital-to-home transitions is pushing institutions to include Rivaroxaban in standardized discharge protocols. Digital health tools are further enhancing adherence by integrating dosing reminders and adverse event tracking, especially for elderly or polymedicated patients. Additionally, multidisciplinary care pathways in stroke prevention now routinely include NOACs, creating a favorable environment for Rivaroxaban. Clinical guideline updates from the American Heart Association (AHA), European Society of Cardiology (ESC), and others continue to endorse NOACs, reinforcing prescriber confidence. As therapeutic inertia diminishes and patient-centered care rises, Rivaroxaban’s versatility positions it to capture share in adjunct and emerging anticoagulation markets.
The Growth in the Rivaroxaban Market Is Driven by Several Factors...
The global rivaroxaban market is expanding due to clinical demand, demographic shifts, and health system adoption patterns. Increasing prevalence of atrial fibrillation, venous thromboembolism, and chronic cardiovascular disease in aging populations is a primary growth driver. Rising preference for NOACs over warfarin-due to ease of administration, improved safety profiles, and elimination of INR monitoring-is accelerating market penetration. Expansion into new indications, such as PAD, ACS, and oncology-related thrombosis, is further unlocking market potential. Ongoing clinical trials and label extensions are supporting therapeutic diversification. Regulatory approvals in emerging markets and improved reimbursement coverage are broadening patient access, particularly in Asia-Pacific and Latin America. The development of cost-effective generics following patent expirations is poised to increase prescription volume, particularly in public healthcare systems. Technological integrations like adherence apps and digital monitoring platforms are improving patient outcomes and supporting long-term therapy continuation. Physician preference, supported by evolving clinical guidelines and real-world evidence, continues to favor Rivaroxaban in hospital and outpatient settings alike. Together, these dynamics position Rivaroxaban as a long-term, globally relevant anticoagulation therapy across a growing range of use cases.
SCOPE OF STUDY:
The report analyzes the Rivaroxaban market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Indication (Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism, Other Indications); Formulation (Tablets, Suspension); Patient Type (Adults, Pediatrics); Distribution Channel (Hospitals & Clinics, Retail Pharmacies, Online Pharmacies)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 41 Featured) -
Aarti Pharmalabs Ltd.
Actoverco Pharmaceutical Co.
Aurobindo Pharma Ltd.
Bayer AG
Celix Pharma Ltd.
Cohance Lifesciences Ltd.
Dr. Reddy's Laboratories Ltd.
Egis Pharmaceuticals PLC
Glenmark Pharmaceuticals Ltd.
Grindeks
Inke S.A.
Janssen Pharmaceuticals, Inc.
LGM Pharma
Lupin Limited
Metrochem API Pvt. Ltd.
Moehs Iberica S.L.
Polpharma
Rochem International Inc.
Suanfarma
Taro Pharmaceutical Industries
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.
We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.
As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.
To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!
APRIL 2025: NEGOTIATION PHASE
Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.
JULY 2025 FINAL TARIFF RESET
Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.
Reciprocal and Bilateral Trade & Tariff Impact Analyses:
USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.
Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.
COMPLIMENTARY PREVIEW
Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Rivaroxaban - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Incidence of Thromboembolic Disorders Propels Demand for Oral Anticoagulants Like Rivaroxaban
Aging Global Population and Increased Prevalence of Atrial Fibrillation Sustain Long-Term Market Growth
Preference for Direct Oral Anticoagulants (DOACs) Over Warfarin Strengthens Business Case for Rivaroxaban
Expanding Off-Label Usage in Stroke Prevention and Post-Surgical Care Throws the Spotlight on Therapeutic Versatility
Improved Patient Adherence Due to Fixed Dosing and No Routine Monitoring Drives Clinical Adoption
Guideline Updates Favoring DOACs in Cardiovascular Treatment Regimens Accelerate Prescriptions
Patent Expiries in Key Markets Generate Competitive Price Pressures and Generic Entry Challenges
Rising Healthcare Expenditures and Reimbursement Coverage Expand Access to Advanced Anticoagulant Therapies
Clinical Trials Supporting Use in Cancer-Associated Thrombosis Fuel Demand in Oncology Segment
Adverse Event Surveillance and Bleeding Risk Concerns Create Opportunities for Safer Formulations
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Rivaroxaban Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Rivaroxaban by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for Rivaroxaban by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 4: World 15-Year Perspective for Rivaroxaban by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Atrial Fibrillation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 6: World Historic Review for Atrial Fibrillation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 7: World 15-Year Perspective for Atrial Fibrillation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Deep Vein Thrombosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 9: World Historic Review for Deep Vein Thrombosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 10: World 15-Year Perspective for Deep Vein Thrombosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Pulmonary Embolism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 12: World Historic Review for Pulmonary Embolism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 13: World 15-Year Perspective for Pulmonary Embolism by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Prophylaxis of Venous Thromboembolism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 15: World Historic Review for Prophylaxis of Venous Thromboembolism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 16: World 15-Year Perspective for Prophylaxis of Venous Thromboembolism by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 18: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 19: World 15-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 21: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 22: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 24: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 25: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 27: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 28: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 29: World Recent Past, Current & Future Analysis for Tablets by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 30: World Historic Review for Tablets by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 31: World 15-Year Perspective for Tablets by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 32: World Recent Past, Current & Future Analysis for Suspension by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 33: World Historic Review for Suspension by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 34: World 15-Year Perspective for Suspension by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 35: World Recent Past, Current & Future Analysis for Adults by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 36: World Historic Review for Adults by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 37: World 15-Year Perspective for Adults by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 38: World Recent Past, Current & Future Analysis for Pediatrics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 39: World Historic Review for Pediatrics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 40: World 15-Year Perspective for Pediatrics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Rivaroxaban Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 41: USA Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 42: USA Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 43: USA 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
TABLE 44: USA Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 45: USA Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 46: USA 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 47: USA Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 48: USA Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 49: USA 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
TABLE 50: USA Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 51: USA Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 52: USA 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
CANADA
TABLE 53: Canada Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 54: Canada Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 55: Canada 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
TABLE 56: Canada Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 57: Canada Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 58: Canada 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 59: Canada Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 60: Canada Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 61: Canada 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
TABLE 62: Canada Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 63: Canada Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 64: Canada 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
JAPAN
Rivaroxaban Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 65: Japan Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 66: Japan Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 67: Japan 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
TABLE 68: Japan Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 69: Japan Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 70: Japan 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 71: Japan Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 72: Japan Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 73: Japan 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
TABLE 74: Japan Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 75: Japan Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 76: Japan 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
CHINA
Rivaroxaban Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 77: China Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 78: China Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 79: China 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
TABLE 80: China Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 81: China Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 82: China 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 83: China Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 84: China Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 85: China 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
TABLE 86: China Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 87: China Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 88: China 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
EUROPE
Rivaroxaban Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 89: Europe Recent Past, Current & Future Analysis for Rivaroxaban by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 90: Europe Historic Review for Rivaroxaban by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 91: Europe 15-Year Perspective for Rivaroxaban by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
TABLE 92: Europe Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 93: Europe Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 94: Europe 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
TABLE 95: Europe Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 96: Europe Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 97: Europe 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 98: Europe Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 99: Europe Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 100: Europe 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
TABLE 101: Europe Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 102: Europe Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 103: Europe 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
FRANCE
Rivaroxaban Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 104: France Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 105: France Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 106: France 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
TABLE 107: France Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 108: France Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 109: France 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 110: France Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 111: France Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 112: France 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
TABLE 113: France Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 114: France Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 115: France 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
GERMANY
Rivaroxaban Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 116: Germany Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 117: Germany Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 118: Germany 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
TABLE 119: Germany Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 120: Germany Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 121: Germany 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 122: Germany Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 123: Germany Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 124: Germany 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
TABLE 125: Germany Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 126: Germany Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 127: Germany 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
ITALY
TABLE 128: Italy Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 129: Italy Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 130: Italy 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
TABLE 131: Italy Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 132: Italy Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 133: Italy 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 134: Italy Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 135: Italy Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 136: Italy 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
TABLE 137: Italy Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 138: Italy Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 139: Italy 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
UNITED KINGDOM
Rivaroxaban Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 140: UK Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 141: UK Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 142: UK 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
TABLE 143: UK Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 144: UK Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 145: UK 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 146: UK Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 147: UK Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 148: UK 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
TABLE 149: UK Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 150: UK Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 151: UK 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
SPAIN
TABLE 152: Spain Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 153: Spain Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 154: Spain 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
TABLE 155: Spain Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 156: Spain Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 157: Spain 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 158: Spain Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 159: Spain Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 160: Spain 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
TABLE 161: Spain Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 162: Spain Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 163: Spain 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
RUSSIA
TABLE 164: Russia Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 165: Russia Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 166: Russia 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
TABLE 167: Russia Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 168: Russia Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 169: Russia 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 170: Russia Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 171: Russia Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 172: Russia 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
TABLE 173: Russia Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 174: Russia Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 175: Russia 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
REST OF EUROPE
TABLE 176: Rest of Europe Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 177: Rest of Europe Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 178: Rest of Europe 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 180: Rest of Europe Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 181: Rest of Europe 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 183: Rest of Europe Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 184: Rest of Europe 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 186: Rest of Europe Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 187: Rest of Europe 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
ASIA-PACIFIC
Rivaroxaban Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 188: Asia-Pacific Recent Past, Current & Future Analysis for Rivaroxaban by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 189: Asia-Pacific Historic Review for Rivaroxaban by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 190: Asia-Pacific 15-Year Perspective for Rivaroxaban by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 192: Asia-Pacific Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 193: Asia-Pacific 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 195: Asia-Pacific Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 196: Asia-Pacific 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 198: Asia-Pacific Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 199: Asia-Pacific 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 201: Asia-Pacific Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 202: Asia-Pacific 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
AUSTRALIA
Rivaroxaban Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
TABLE 203: Australia Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 204: Australia Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 205: Australia 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
TABLE 206: Australia Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 207: Australia Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 208: Australia 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 209: Australia Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 210: Australia Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 211: Australia 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
TABLE 212: Australia Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 213: Australia Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 214: Australia 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
INDIA
Rivaroxaban Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
TABLE 215: India Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 216: India Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 217: India 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
TABLE 218: India Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 219: India Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 220: India 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 221: India Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 222: India Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 223: India 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
TABLE 224: India Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 225: India Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 226: India 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
SOUTH KOREA
TABLE 227: South Korea Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 228: South Korea Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 229: South Korea 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
TABLE 230: South Korea Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 231: South Korea Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 232: South Korea 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 233: South Korea Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 234: South Korea Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 235: South Korea 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
TABLE 236: South Korea Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 237: South Korea Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 238: South Korea 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
REST OF ASIA-PACIFIC
TABLE 239: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 240: Rest of Asia-Pacific Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 241: Rest of Asia-Pacific 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 243: Rest of Asia-Pacific Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 244: Rest of Asia-Pacific 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 246: Rest of Asia-Pacific Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 247: Rest of Asia-Pacific 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 249: Rest of Asia-Pacific Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 250: Rest of Asia-Pacific 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
LATIN AMERICA
Rivaroxaban Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
TABLE 251: Latin America Recent Past, Current & Future Analysis for Rivaroxaban by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 252: Latin America Historic Review for Rivaroxaban by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 253: Latin America 15-Year Perspective for Rivaroxaban by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
TABLE 254: Latin America Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 255: Latin America Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 256: Latin America 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
TABLE 257: Latin America Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 258: Latin America Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 259: Latin America 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 260: Latin America Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 261: Latin America Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 262: Latin America 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
TABLE 263: Latin America Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 264: Latin America Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 265: Latin America 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
ARGENTINA
TABLE 266: Argentina Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 267: Argentina Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 268: Argentina 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
TABLE 269: Argentina Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 270: Argentina Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 271: Argentina 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 272: Argentina Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 273: Argentina Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 274: Argentina 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
TABLE 275: Argentina Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 276: Argentina Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 277: Argentina 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
BRAZIL
TABLE 278: Brazil Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 279: Brazil Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 280: Brazil 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
TABLE 281: Brazil Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 282: Brazil Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 283: Brazil 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 284: Brazil Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 285: Brazil Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 286: Brazil 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
TABLE 287: Brazil Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 288: Brazil Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 289: Brazil 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
MEXICO
TABLE 290: Mexico Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 291: Mexico Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 292: Mexico 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
TABLE 293: Mexico Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 294: Mexico Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 295: Mexico 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 296: Mexico Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 297: Mexico Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 298: Mexico 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
TABLE 299: Mexico Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 300: Mexico Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 301: Mexico 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
REST OF LATIN AMERICA
TABLE 302: Rest of Latin America Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 303: Rest of Latin America Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 304: Rest of Latin America 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 306: Rest of Latin America Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 307: Rest of Latin America 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 309: Rest of Latin America Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 310: Rest of Latin America 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 312: Rest of Latin America Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 313: Rest of Latin America 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
MIDDLE EAST
Rivaroxaban Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
TABLE 314: Middle East Recent Past, Current & Future Analysis for Rivaroxaban by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 315: Middle East Historic Review for Rivaroxaban by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 316: Middle East 15-Year Perspective for Rivaroxaban by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
TABLE 317: Middle East Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 318: Middle East Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 319: Middle East 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
TABLE 320: Middle East Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 321: Middle East Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 322: Middle East 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 323: Middle East Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 324: Middle East Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 325: Middle East 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
TABLE 326: Middle East Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 327: Middle East Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 328: Middle East 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
IRAN
TABLE 329: Iran Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 330: Iran Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 331: Iran 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
TABLE 332: Iran Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 333: Iran Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 334: Iran 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 335: Iran Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 336: Iran Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 337: Iran 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
TABLE 338: Iran Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 339: Iran Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 340: Iran 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
ISRAEL
TABLE 341: Israel Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 342: Israel Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 343: Israel 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
TABLE 344: Israel Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 345: Israel Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 346: Israel 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 347: Israel Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 348: Israel Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 349: Israel 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
TABLE 350: Israel Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 351: Israel Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 352: Israel 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
SAUDI ARABIA
TABLE 353: Saudi Arabia Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 354: Saudi Arabia Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 355: Saudi Arabia 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 357: Saudi Arabia Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 358: Saudi Arabia 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 360: Saudi Arabia Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 361: Saudi Arabia 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 363: Saudi Arabia Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 364: Saudi Arabia 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
UNITED ARAB EMIRATES
TABLE 365: UAE Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 366: UAE Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 367: UAE 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
TABLE 368: UAE Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 369: UAE Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 370: UAE 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 371: UAE Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 372: UAE Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 373: UAE 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
TABLE 374: UAE Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 375: UAE Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 376: UAE 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
REST OF MIDDLE EAST
TABLE 377: Rest of Middle East Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 378: Rest of Middle East Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 379: Rest of Middle East 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 381: Rest of Middle East Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 382: Rest of Middle East 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 384: Rest of Middle East Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 385: Rest of Middle East 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 387: Rest of Middle East Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 388: Rest of Middle East 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
AFRICA
Rivaroxaban Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
TABLE 389: Africa Recent Past, Current & Future Analysis for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 390: Africa Historic Review for Rivaroxaban by Indication - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 391: Africa 15-Year Perspective for Rivaroxaban by Indication - Percentage Breakdown of Value Sales for Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism and Other Indications for the Years 2015, 2025 & 2030
TABLE 392: Africa Recent Past, Current & Future Analysis for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 393: Africa Historic Review for Rivaroxaban by Distribution Channel - Hospitals & Clinics, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 394: Africa 15-Year Perspective for Rivaroxaban by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Clinics, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
TABLE 395: Africa Recent Past, Current & Future Analysis for Rivaroxaban by Formulation - Tablets and Suspension - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 396: Africa Historic Review for Rivaroxaban by Formulation - Tablets and Suspension Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 397: Africa 15-Year Perspective for Rivaroxaban by Formulation - Percentage Breakdown of Value Sales for Tablets and Suspension for the Years 2015, 2025 & 2030
TABLE 398: Africa Recent Past, Current & Future Analysis for Rivaroxaban by Patient Type - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 399: Africa Historic Review for Rivaroxaban by Patient Type - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 400: Africa 15-Year Perspective for Rivaroxaban by Patient Type - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030